HAYWARD, Calif., Nov. 29, 2011 /PRNewswire/ -- Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced that its arhalofenate program has been recognized in Windhover's "Top 10 most interesting cardiovascular/metabolic diseases projects to watch." Arhalofenate is a potential best-in-class treatment for gout that not only treats the hyperuricemia that causes gout, but also addresses aspects of the metabolic abnormalities that are prevalent amongst patients with gout. Arhalofenate was selected by a panel of independent experts who screen hundreds of compounds and weigh their potential as future products. These independent experts include Campbell Alliance, NI Research, Healogix, Wolpert Associates, Cobbs Creek Healthcare and Herndon Associates.
"We are honored to receive this significant recognition of our program. It underscores arhalofenate's potential to become an important new therapy in the treatment of gout," said Harold Van Wart, Ph.D., Chief Executive Officer of Metabolex.
The selected companies have been screened using a strict set of judging criteria, including unmet medical need, market potential, diversity of indications, strong science, multi-level partnering opportunities (biotech and pharma), potential for new opportunities beyond initial indications, and corporate stability. Each project has been hand-selected by Windhover's elite selection panel to ensure a high-quality slate of presenters. "This year's list is handpicked in the six hottest therapeutic areas," said David Cassak, VP, Content, for Elsevier Business Intelligence's publications. "Many of the companies we selected in the past have gone on to do big deals, and we expect the same from this years' companies. 90% of the companies haven't presented at major partnering events this year."
Metabolex plans to present information on arh
|SOURCE Metabolex, Inc.|
Copyright©2010 PR Newswire.
All rights reserved